Table III.
Comparison of clinical features and outcomes of patients between the ulinastatin treatment group and standard care group.
| Characteristic | Ulinastatin treatment group (n=12) | Standard care group (n=15) | Statistics | P-value |
|---|---|---|---|---|
| Median age, years (IQR) | 72.0 (56.3, 76.3) | 75.0 (68.0, 83.0) | t=0.970 | 0.341a |
| Male sex, n (%) | 10 (83.3) | 10 (66.7) | 0.408b | |
| Comorbidities | ||||
| Hypertension, n (%) | 8 (66.7) | 6 (40.0) | χ2=1.899 | 0.168c |
| DM, n (%) | 2 (16.7) | 3 (20.0) | 1.000b | |
| CCVD, n (%) | 2 (16.7) | 8 (53.3) | 0.107b | |
| COPD, n (%) | 1 (8.3) | 3 (20.0) | 0.605b | |
| Disease severity status on admission | 0.696b | |||
| Mild/moderate, n (%) | 3 (25.0) | 5 (33.3) | ||
| Severe, n (%) | 9 (75.0) | 10 (66.7) | ||
| Baseline laboratory parameters | ||||
| Median WBC count, x109/l (IQR) | 5.4 (4.2, 8.5) | 6.9 (6.2, 11.3) | t=1.446 | 0.161a |
| Median lymphocytes, % (IQR) | 19.3 (8.8, 25.1) | 10.9 (6.9, 22.1) | t=1.168 | 0.254a |
| Median CRP, mg/l (IQR) | 25.2(5.9,58.1) | 50.9 (8.6, 89.3) | t=0.189 | 0.851a |
| Transition to more severe cases, n (%) | 1 (8.3) | 7 (46.7) | 0.043b | |
| Oxygen therapy | 1.000b | |||
| Non-invasive ventilator support, n (%) | 12 (100.0) | 14 (93.3) | ||
| Ventilator support, n(%) | 0 (0.0) | 1 (6.7) | ||
| Clinical outcome | 0.106b | |||
| Discharged, n (%) | 12 (100.0) | 11 (73.3) | ||
| Death, n (%) | 0 (0.0) | 4 (26.7) |
aUnpaired student's t-test;
bFisher's exact test;
cχ2 test. IQR, interquartile range; DM, diabetes mellitus; CCVD, cardio-cerebrovascular disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; CRP, C-reactive protein.